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Abstract
Purpose To evaluate the diagnostic accuracy of contrast-
enhanced FDG-PET/CT (ce-PET/CT), PET-only, and CT-
only in patients with newly diagnosed and resected
cutaneous malignant melanoma.
Methods A final group of 56 patients (mean age 62 years,
range 23–86 years; 29 women, 27 men) were staged with
ce-PET/CT after resection of the primary tumour. Histopa-
thology as well as clinical follow-up (mean 780 days, range
102–1,390 days) served as the standards of reference.
Differences between the staging modalities were tested for
statistical significance with McNemar’s test.
Results All imaging procedures provided low sensitivities
in the detection of lymph nodes (sensitivity N-stage: PET/
CT and PET-only 38.5%; CT-only 23.1%) and distant
metastases (sensitivity M-stage: PET/CT 41.7%, PET-only
33.3%, CT-only 25.0%) in initial staging after resection of
the primary tumour. No statistically significant differences
were detected between the imaging procedures (p>0.05).
PET/CT resulted in an alteration in further treatment in two
patients compared to PET-only and in four patients
compared to CT-only.
Conclusion All imaging modalities had a low sensitivity
on initial staging of patients with malignant melanoma.
Thus, close patient follow-up must be considered
mandatory.
Keywords ce-PET/CT. Cutaneous melanoma . Staging .
Follow-up . Diagnostic accuracy
Introduction
The incidence of melanoma has been increasing worldwide,
especially in the Caucasian population [1]. In 2007
approximately 60,000 new cases of melanoma were
diagnosed and over 8,000 patients were expected to die
from this disease in the United States. The patients’
prognosis strongly depends on the tumour depth (tumour
thickness and Breslow index), potential ulceration, and the
presence of metastases [2, 3]. Cutaneous melanoma is
considered curable in patients if the tumour is <2 mm deep,
is without ulceration, and is without lymph node metasta-
ses. Tumours of higher tumour stages are considered to
have an advanced likelihood of metastatic spread. Thus,
overall survival is heavily dependent on the stage of the
primary tumour [4, 5].
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Several imaging methods are considered appropriate for
imaging patients with malignant melanoma and potential
metastatic spread. Computed tomography (CT) is widely
accepted and recommended for detection of organ metas-
tases [6, 7]. However, CT has a limited sensitivity for the
detection of lymph node metastases because of its strict
morphological nature. Locoregional ultrasonography has
been used for assessment of lymph nodes, but is investiga-
tor-dependent and strictly morphological.
To overcome the lack of functional data, positron
emission tomography (PET) using [18F]-fluoro-2-deoxy-D-
glucose (FDG) as a radioactive tracer has gained wide
acceptance in patients with malignant melanoma in partic-
ular in patients with clinical suspicion of systemic meta-
static spread [8, 9]. However, the accuracy of FDG-PET in
initial staging of malignant melanoma has rarely been
assessed. PET-only imaging can be impaired based on its
lack of anatomical resolution. Hence, complementary
anatomical imaging is often required, especially for surgical
therapy planning. Coregistered PET/CT has been available
since 2001 and provides such anatometabolic datasets in a
single examination. PET/CT has been found to be superior
to CT alone and PET alone in staging and evaluation of
therapy response in several oncological diseases including
malignant melanoma [10–12]. However, as mentioned
above, there is currently only little knowledge concerning
the accuracy of FDG-PET/CT compared to CT alone and
PET alone for initial staging of malignant melanoma. Thus,
the aim of our study was (1) to evaluate the accuracy of
FDG-PET/CT, CT-only, and PET-only for initial staging of
malignant melanoma using long-term follow-up and
histopathology as the standards of reference, and (2) to
assess the potential impact of FDG-PET/CT on patient
management.
Materials and methods
Patients
Seventy-four patients were included based on their order of
referral without further selection. All patients were referred
for a combined FDG-PET/CT examination after surgical
resection of a primary malignant melanoma. This prospec-
tive study was performed in accordance with the regu-
lations of the local institutional review board and ethics
committee. All patients were included consecutively based
on the time of referral without further selection. Patients
were excluded from the analysis if no sufficient follow-up
data were available (e.g. patient did not attend for follow-up
examinations or decided to have follow-up at another
institution). Informed consent was obtained from all
patients prior to the examination.
FDG-PET/CT imaging procedure
Patients were instructed to fast for at least 4 h prior to the
PET/CT procedure. Glucose levels in all patients were
measured prior to FDG injection to ensure they were in the
normal range. PET/CT imaging was conducted on a
Biograph Duo PET/CT system (Siemens Molecular Imag-
ing, Hoffman Estates, IL). The system integrates a dual-
slice CT scanner (Somatom Emotion, Siemens Medical
Solutions, Forchheim, Germany) and a full-ring, BGO-
based PET tomograph (Siemens Molecular Imaging). The
axial field-of-view of the PET scanner is 15.5 cm per bed
position, and the in-plane spatial resolution is 4.6 mm,
respectively. The average FDG activity administered 60 min
prior to the PET/CTexamination was 330–350 MBq. During
the uptake time, 1,500 ml of a water-based, water-equivalent
oral contrast agent was administered to all patients for small-
bowel distension [13].
During the whole-body CT examination (part of the
PET/CT examination), 140 ml of iodinated contrast agent
(300 mmol/ml, Xenetix 300; Guerbet, Sulzbach, Germany)
was administered intravenously according to a standardized
protocol [14]. The CT scan was performed in the
caudocranial direction. A start delay of 50 s was chosen
for the CT acquisition after the start of the contrast agent
injection. The first 90 ml of contrast agent were injected at
a rate of 3 ml/s, and the remaining 50 ml were injected at a
rate of 1.5 ml/s. The dual-phase injection was intended to
ensure fully diagnostic (portal venous phase) CT data in the
abdomen. The contrast-enhanced CT scan was used for
attenuation correction of the PET data. The PET acquisition
time per bed position was 3–5 min, depending on the
weight of the patient. PET images were corrected for scatter
and attenuation based on the available CT transmission
images. Corrected PET images were reconstructed itera-
tively (FORE-OSEM, two iterations, eight subsets, 128×
128 matrix with 5-mm gaussian smoothing). CT images as
well as PET data sets were viewed separately (CT-only,
PET-only), and in fused mode (PET/CT) on a commer-
cially available computer workstation (Siemens Molecular
Imaging). Therefore, all imaging modalities compared
were derived from the same dataset.
Image evaluation
N-staging and M-staging
The T-stage was documented from the histological speci-
mens from the surgical resection, which was performed not
more than 1 week prior to the imaging procedure. N-staging
and M-staging evaluation were performed for CT-only,
PET-only, and coregistered FDG-PET/CT. The PET images
were evaluated with and without attenuation correction by
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two nuclear medicine specialists in consensus. The CT
images were evaluated by two radiologists in consensus.
Contrast-enhanced PET/CT (ce-PET/CT) images were
evaluated by a different radiologist and nuclear medicine
specialist in consensus. The participating readers were
informed about the patient-specific clinical background
(first diagnosis of melanoma, postsurgical resection
status, location of the resection site), but blinded to the
results of histopathology of the primary tumour, and
blinded to the other imaging procedures and to clinical
examination.
Distant metastases were assessed based on the detec-
tion of soft-tissue masses (or focal cutaneous thickening)
with contrast enhancement in different body compart-
ments and in conjunction with focally increased glucose
metabolism above the surrounding tissue level on FDG-
PET/CT. The diagnosis of a distant metastasis was also
supported by an maximum standardized uptake value
(SUVmax) of at least 1.5 for cutaneous lesions, 2.5 for
other extrahepatic lesions, and 3.5 for intrahepatic lesions
[15]. However, the SUVmax was not taken as the absolute
threshold to differentiate between malignant and benign
findings. In fact, the qualitative assessment was taken as
the most important parameter. If a lesion showed clear
focal FDG avidity but displayed a lower SUVmax (e.g.
due to small size), the lesion was rated malignant. In cases
of malignant findings on CT-only without focally in-
creased glucose metabolism, the lesions were evaluated
based on CT criteria (see below). Lymph nodes were
assessed for metastatic spread based on an increased
glucose metabolism and independent of their size on
PET/CT images.
On CT-only images, detection of soft-tissue masses (or
focal cutaneous thickening) with contrast enhancement
characterized malignancy. Lymph node assessment was
based on lesion size: a short-axis diameter threshold of
1.5 cm was used for jugulodigastric lymph nodes and
precarinal lymph nodes. A short-axis diameter threshold of
1 cm was used for all other lymph nodes of the neck,
thorax, and abdomen [16]. Central necrosis was defined as
a sign of malignancy as well, independent of lymph node
size. Furthermore, according to standard CT criteria, a fatty
hilum and calcifications were used as benign criteria on CT-
only images.
PET-only images were assessed qualitatively and quan-
titatively for areas of increased FDG uptake. Lesions
(distant metastasis and lymph nodes) were called malignant
if the glucose utilization exceeded the surrounding tissue or
blood pool level. As in evaluation of the PET/CT images,
the diagnosis of metastases was also supported by a
SUVmax of more than 1.5 for cutaneous lesions, more
than 2.5 for extrahepatic lesions, and more than 3.5 for
intrahepatic lesions. The N-stage and M-stage in all patients
were assessed based on the current AJCC criteria for all
imaging modalities [17].
The impact of FDG-PET/CT imaging on patient man-
agement as compared to PET-only and CT-only was
assessed in consensus by the referring physicians and a
radiologist and nuclear medicine specialist each, and
evaluation was based on international clinical guidelines
[6, 18].
Standard of reference
Initial clinical staging derived from histopathological
examination of the primary tumour (T-stage) after
resection, from sentinel lymph node resection within
4 weeks of PET/CT imaging and all other available
clinical studies and imaging studies (MRI, radiography,
ultrasonography, tumour markers). Because PET/CT
imaging was the modality to be evaluated, the results
of the PET/CT imaging were not taken into account for
the definition of the initial clinical stage. Sentinel lymph
node imaging and resection were performed within
4 weeks of initial PET/CT imaging. In all patients with
suspected metastases on imaging, histopathological eval-
uation and the resected surgical specimen (tumours and/
or lymph nodes) of at least one metastatic site served as
the standard of reference for both N-stage and M-stage
during the clinical course. For all other patients, clinical
follow-up including all clinically available data (imaging,
tumour markers, physical examination) served as the
standard of reference.
Statistical analysis
The primary endpoint of the study was the correct
classification of the N-stage and M-stage using CT-only
or PET-only in comparison to fused PET/CT. Differences in
the assessment of the N-stage and M-stage between the
different imaging procedures were tested for significance by
McNemar’s test (exact). Bonferroni correction was applied
to account for multiple comparisons. To maintain a global
significance level of 0.05 the nominal significance level to
evaluate the four hypotheses of the primary analysis had to
be 0.0125. We calculated 95% confidence intervals (CI)
according to the method of Tango for the difference in
correlated proportions of the correct N-stage and M-stage
[19]. Sensitivities, specificities, negative predictive values
(NPV), positive predictive values (PPV), and accuracies
(with exact 95% confidence intervals) for all modalities
were determined for N-stage assessment and for M-stage
assessment using histology and/or clinical follow-up as the
standard of reference.
Statistical analyses were performed with SAS statistical
software (version 9.1; SAS Institute, Cary, NC).
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Results
Patients
Included in this prospective study were 74 consecutive
patients who underwent combined PET/CT imaging in a
University Hospital setting. Of these 74 patients, 18 were
excluded because of a lack of sufficient follow-up, leaving
56 patients for final evaluation (mean age 62 years, range
23–86 years; 29 women, 27 men) (Table 1). The T-stage of
the primary, melanoma location, histological type of the
melanoma and the clinical stages according to the standard
of reference are given in Table 1 for the 56 evaluated
patients. Overall, the mean follow-up time was 780 days
(range 102–1,390 days). A total 18 patients had metastases,
in 12 detected at initial staging (clinical stage III or IV), and
in the other 6 during the clinical course. Sentinel lymph
node imaging and resection was performed within 4 weeks
of the initial PET/CT procedure in 14 patients. Overall, at
least one suspicious lesion was confirmed histologically in
all patients suspected of harbouring metastases in lymph
nodes or distant organs during the clinical course. During
the follow-up 28 patients remained disease-free. Four
patients died during the clinical course. In one patient, a
secondary cancer (breast cancer) was detected at initial
staging. All patients tolerated the PET/CT procedures well.
Metastases at initial staging
At initial staging, 12 patients were diagnosed with lymph
node and/or distant metastases. The initial clinical stages
were stage IV in eight patients and stage III in four patients.
Combining the T-stage from histopathology with the
staging results from FDG-PET/CT, PET-only and CT-only,
the tumour stage was correctly classified in six patients
with PET/CT, in five patients with PET, and in three
patients with CT. No statistically significant difference was
detected concerning the N-stage and the M-stage when
comparing PET/CT and PET-only (p>0.05), PET/CT and
CT-only (p>0.05) in this subgroup of patients.
Overall N-staging/M-staging
A comparison of the N-stages and M-stages for all imaging
modalities are shown in Table 2. Overall, no statistically
significant differences were detected concerning the N-stage
between PET/CT and PET-only (difference 0%; 95% CI −10–
10%; p>0.05) or between PET/CT and CT-only (difference
4%; 95% CI −15–7%; p>0.05). Additionally, no statistically
significant differences were found concerning the M-stage
between PET/CT and PET-only (difference −2%; 95%
CI −12–8%; p>0.05) or between PET/CT and CT-only
(difference −2%; 95% CI −12–8%; p>0.05).
Therapy alteration, occurrence of metastases and side
findings
N-stage
In two patients, PET/CT and PET-only were superior to
CT-only because lymph nodes with focal FDG avidity
were not evaluated as malignant on CT-only due to size
criteria. In these two patients these findings were thera-
peutically relevant, because both lymph node metastases
were identified and treated consecutively after the initial
scan.
Overall (during the whole clinical course including
initial staging), eight patients were falsely staged as
negative on PET/CT and PET-only concerning lymph node
metastases and ten patients were falsely staged as negative
on CT-only (Table 2). Two of these patients had micro-
metastases at initial staging which were overlooked on all
imaging modalities but detected by sentinel lymph node
resection after PET/CT imaging.
M-stage
Overall, in four patients, therapeutically relevant advan-
tages arose from PET/CT imaging concerning the M-stage.
In one patient, PET/CT detected small pulmonary nodules
without FDG activity, which were evaluated as lung
metastases based on the CT part of the PET/CT scan.
However, these lesions were overlooked on PET-only (but
detected by CT-only), based on their size and lack of FDG
activity. Pulmonary metastases were confirmed on clinical
follow-up.
In another patient, PET-only imaging showed an
increased FDG uptake in an adrenal gland, but the CT
component of the PET/CT scan showed no morphological
correlate. Thus, on the PET/CT image, the readers
evaluated this finding as not pathological, while on the
PET-only image the readers considered the possibility of
adrenal gland metastases. During the following clinical
course, no adrenal gland metastasis was detected in this
patient.
PET/CT had a therapeutically relevant advantage in
another patient, in whom a pathologically enlarged inguinal
lymph node was evaluated as malignant on CT-only. PET/
CT showed no increased glucose metabolism. Thus, the
lymph node was evaluated as normal on PET/CT which
was confirmed during the clinical course. PET/CT had a
therapeutically relevant advantage in another patient in
whom (vice versa) the readers detected increased glucose
metabolism in a lymph node that was not pathologically
enlarged on PET/CT. The PET/CT image was evaluated
correctly as malignant, while the CT-only image was
evaluated falsely as negative (Fig. 1).
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Table 1 Patient characteristics, locations of the primary tumour, histological type of melanoma, and clinical stage
Patient no. Age (years) Location Histological type S-100 (mg/l)a Clinical stageb
1 59 Left back Nodular 0.11 I A
2 53 Right breast Superficial spreading 0.15 I A
3 58 Left shoulder Superficial spreading 0.057 III
4 48 Left thigh Nodular 0.016 I B
5 69 Right lower leg Superficial spreading II A
6 45 Left lower leg Superficial spreading 0.168 II A
7 69 Left upper arm Superficial spreading 0.132 II A
8 79 Left face Lentigo maligna 0.027 I A
9 71 Right upper arm Nodular IV
10 47 Right thigh Superficial spreading I A
11 83 Right foot Nodular 0.093 II A
12 35 Right forearm Lentigo maligna 0.042 II A
13 69 Right knee Superficial spreading 0.07 I B
14 70 Right hand Superficial spreading 0.136 IV
15 86 Right lower leg Nodular 0.402 IV
16 59 Right upper arm Nodular IV
17 46 Right lower back Superficial spreading <0.15 IV
18 48 middle back Lentigo maligna 0.024 I B
19 69 Right thorax Nodular 0.087 II A
20 65 Right thorax Nodular IV
21 57 Right abdomen Superficial spreading I A
22 65 Right upper arm Superficial spreading 0.078 I A
23 46 Left back Superficial spreading IV
24 48 Right knee Nodular 0.066 II C
25 53 Left back Superficial spreading 0.038 I B
26 73 Right face Nodular 0.075 II B
27 39 Left hip Superficial spreading I A
28 83 Left forearm Nodular II A
29 79 Right back Superficial spreading I A
30 41 Right lower back Superficial spreading I B
31 42 Left thorax Superficial spreading 0.045 I A
32 59 Left thorax Nodular 0.095 IV
33 57 Right thorax Nodular IV
34 77 Right forearm Nodular 0.116 I B
35 65 Right thorax Superficial spreading IV
36 23 Right lower leg Superficial spreading 0.117 I A
37 82 Right groin Nodular II B
38 62 Right upper arm Nodular I B
39 79 Right foot Acrolentiginous II B
40 75 Left abdomen Superficial spreading 0.139 II B
41 66 Right thigh Nodular III
42 76 Right back Superficial spreading 0.056 I B
43 79 Left back Acrolentiginous III
44 68 Right back Superficial spreading 0.12 I B
45 70 Right thorax Superficial spreading 0.092 IV
46 56 Left knee Nodular I B
47 73 Right shoulder Superficial spreading 0.086 II A
48 71 Right lower leg Superficial spreading 0.133 IV
49 55 Right lower leg Nodular II A
50 74 Left shoulder Superficial spreading 0.075 IV
51 60 Left upper arm Superficial spreading I A
52 40 Right abdomen Superficial spreading I B
53 59 Left thigh Lentigo maligna III
54 84 Left upper arm Nodular 0.08 I B
55 32 Right thorax Superficial spreading IV
56 49 Left thigh Nodular II C
a Standard tumour marker measured at initial diagnosis.
b Evaluated based on the standard of reference; thus, clinical results within the follow-up time were also included.
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Overall, 18/56 patients (32%) had either metastases at
initial staging (12 patients) or developed metastases during
the clinical course. Of these 18 patients, 12 (21%) presented
initially with clinical stage III or IV, and 6 (11%) initially
staged as clinical stage I or II, developed local lymph node
metastases and/or distant metastases (Fig. 2).
Overall, in patients classified as false-negative, lymph
node metastases were detected after a mean follow-up time
of 150 days (range 15–425 days), and distant metastases
were detected after a mean follow-up time of 204 days
(range 71–558 days).
Discussion
Both functional and morphological imaging procedures
have a low sensitivity when assessing patients with
cutaneous malignant melanoma for locoregional and distant
metastases at initial diagnosis. In metastasis-negative
patients this has to be taken into account and should
mandate a close patient follow-up.
Currently there is only little knowledge about FDG-PET/
CT and its role as a first-line diagnostic tool or follow-up
imaging modality in malignant melanoma. However,
different studies have found a benefit of PET-only when
compared with CT imaging in patients with recurrent
melanoma [8]. Fuster et al. reported an FDG-PET sensitiv-
ity and specificity of 74% and 86% for lesion detection in
patients with melanoma compared with 58% and 54% for
standard imaging [20]. Crippa et al. found an even higher
accuracy of FDG-PET imaging. In their study the sensitiv-
ity, specificity and accuracy, and the PPV and NPV for
detection and characterization of lymph node metastases
were 95%, 84%, 91%, 92%, and 89%, respectively [21]. In
another patient population with a primary diagnosis of
melanoma, which may thus be comparable to our popula-
tion, a lesion-based sensitivity of 94.9% was found [22].
These overall promising results of PET imaging were
confirmed by Reinhardt et al. who evaluated a mixed
patient population comprising 250 patients with a primary
diagnosis, therapy control, recurrence, and follow-up on
FDG-PET/CT imaging [10]. The sensitivity, specificity, and
accuracy for the N-stage and M-stage in the entire patient
population ranged between 95% and 100% for PET/CT
imaging. The substantial differences between previously
reported sensitivities and the sensitivities in our study can
be attributed to several factors. Most previous studies
included a limited follow-up time. We followed our patients
over a mean period of over 2 years, compared to 1 year in
the study by Reinhardt et al. and most of the other studies.
Table 2 Staging results
Stage Modality Correctly
staged
Overstaged Understaged Sensitivity
(95% CI) (%)
Specificity
(95% CI) (%)
Accuracy
(95% CI) (%)
NPV
(95% CI) (%)
PPV
(95% CI) (%)
N PET/CT 48/56 0/56 8/56 38.5 (14–68) 100 (92–100) 85.6 (74–94) 84.3 (71–93) 100 (48–100)
PET-only 48/56 0/56 8/56 38.5 (14–68) 100 (92–100) 85.7 (74–94) 84.3 (71–93) 100 (48–100)
CT-only 46/56 0/56 10/56 23.1 (5–53) 100 (92–100) 82.1 (70–91) 81.1 (68–91) 100 (48–100)
M PET/CT 46/56 3/56 7/56 41.7 (15–72) 93.2 (81–99) 82.1 (70–91) 85.4 (72–94) 62.5 (24–91)
PET-only 44/56 4/56 8/56 33.3 (9–65) 90.9 (78–97) 78.6 (66–88) 83.3 (70–93) 50.0 (16–84)
CT-only 44/56 3/56 9/56 25.0 (5–57) 93.2 (81–99) 78.6 (66–88) 82.0 (69–91) 50.0 (12–88)
Fig. 1 A 66-year-old female
after resection of a malignant
melanoma of the right thigh. a A
small lymph node that is not
pathologically enlarged is seen
on the CT-only image dorsal to
the right external iliac vessels.
However, based on size criteria,
the lymph node was not evalu-
ated as malignant. b On the
corresponding PET/CT image,
the same lymph node is seen as
FDG avid and was thus evalu-
ated as metastasis
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It is well known that with an increase in follow-up time, the
incidence of metastases increases. Metastases which oc-
curred during the clinical course and were not detected on
initial FDG-PET/CT imaging were rated as false-negative
in our analysis. We chose this approach because the
primary melanoma had already been resected. Metastases
developing in the further course of disease must, therefore,
have been present as micrometastases before. Small
metastatic cell deposits need to have a certain size to be
detected by FDG-PET or FDG-PET/CT imaging. It has
been shown that cell conglomerates of 78 mm3 are needed
for PET-only imaging to provide a sensitivity of 90% [23].
As the detectors of the PET component of PET/CT are
similar to those in PET-only no additional sensitivity of
FDG-PET/CT over FDG-PET can be expected. However,
rating the imaging findings as false-negative in the presence
of micrometastases has been a matter of controversy, as
metastases detected at a later time may have resulted from
small cell deposits in other organs. Yet metastatic cells
might circulate over a certain period of time, probably
depending on the immunological status of the patient. In
this case, detection of lymph nodes or organ metastases
must be considered impossible with current imaging
techniques. However, this would still result in a false-
negative assessment for metastatic spread on initial staging
and stresses the need for a close follow-up in metastasis-
negative patients.
Another major difference compared to the study of
Rheinhardt et al. was the finding of metastases in 35% of
the 76 patients at initial staging, while in our study only
21% of the patients (12/56) had metastases by the time of
first diagnosis. Consequently, therapy changes occurred in a
significantly higher percentage (43% in patients with
primary diagnosis of melanoma) compared to our patient
population. It is already known from PET imaging studies
that the impact on therapy and staging increases in higher
clinical stages [24]. However, there are also studies in the
literature that have shown low sensitivities of FDG-PET in
malignant melanoma. In a study including patients with
early-stage melanoma, the sensitivity to detect lymph node
metastases was only 21% [25]. Based on these results FDG-
PET was not recommended as a first-line tool to stage
malignant melanoma. Also in this study, the follow-up time
was significantly longer than 1 year (>41 months).
As sentinel lymph node imaging and biopsy should be
considered in stages I and II and is definitively recom-
mended by staging guidelines in higher stages, it should be
applied at least in patients with advanced clinical stages [6].
Fig. 2 A 59-year-old male after resection of a malignant melanoma of
the left dorsal thorax (initial clinical stage II). a–c On initial staging 12
days after resection of the primary tumour, no right axillary distant
metastases are seen on the CT-only (a), PET/CT (b) or PET-only (c)
images. d–f During follow-up, a distant metastasis in the right axilla is
seen on the CT-only (d), PET/CT (e) and PET-only (f) images
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If positive, the next staging step and follow-up could be
combined PET/CT imaging (PET imaging is recommended in
staging guidelines anyway) for several reasons. First, it has
already been shown (also partly in our study), that PET/CT
imaging can correctly change the subsequent therapy and
therefore might decrease rates of morbidity compared to CT-
only and PET-only [10, 26]. PET/CT imaging has also been
found to be useful for the follow-up of patients with resected
melanoma because it provides detection of metastases, even
when tumour markers are negative, and it can furthermore
improve the detection of melanoma metastases compared to
PET-alone [11, 12]. An efficient follow-up imaging algo-
rithm (as proposed here) has to be collaboratively developed
because 11% of our patients developed metastases despite
the initially low clinical stage.
Our study has several limitations concerning compara-
bility with other studies. Our whole-body CT protocol was
different from that used in the study by Reinhardt et al. in
which no intravenous contrast medium was administered.
However, since PET/CT is a combined imaging modality,
we believe that adequate image quality should be provided
in both imaging parts (CT and PET). An additional reason
for the differences was the relatively low number of patients
with metastases at initial staging and during the clinical
course in our study. However, we included our patients
prospectively with no further selection thus, reflecting the
clinical routine in our department.
Sentinel lymph node biopsy was not available in every
patient because there are no strict guidelines recommending
this in every melanoma case (see guidelines and discussion
above). However, there is evidence that sentinel lymph
node imaging and resection is more sensitive than PET
imaging alone, especially in stage I and II disease [27–30].
Currently there is no study available comparing the
sensitivity of sentinel lymph node imaging and PET/CT
imaging (there are studies comparing sentinel lymph node
imaging to PET-only), but since the CT part in PET/CT
generally does not increase the sensitivity in lymph node
detection, it can be assumed that these data are still valid.
We did not have the standard tumour marker available in
every patient (S-100, see Table 1) because only lactate
dehydrogenase is optionally included in a guideline-
oriented standard work-up in advanced clinical stages. It
has already been demonstrated, that the S-100 marker also
has a limited ability to detect melanoma metastases
compared to PET/CT imaging [12].
Conclusion
Based on our results, ce-FDG-PET/CT can only be
recommended as a first-line diagnostic tool for selected
melanoma patients in the high-risk group. Generally, ce-
FDG-PET/CT and FDG-PET have low sensitivities on
initial staging of patients with malignant melanoma. Thus,
close patient follow-up must be considered mandatory.
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